Related Experiment Video

Updated: Mar 17, 2026

A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals
07:39

A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals

Published on: June 25, 2018

7.8K

Antioxidant effect of angiotensin (1‑7) in the protection of pancreatic β cell function

Fen Zhang1, Chang Liu1, Lei Wang1

  • 1Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, P.R. China.

Molecular Medicine Reports
|July 20, 2016
PubMed

Insights

Angiotensin (1-7) protects pancreatic beta cells from oxidative stress, a key factor in diabetes. This protective effect, mediated by the ACE2/Ang (1-7)/Mas axis, was confirmed using cell models and reversed by an antagonist.

Area of Science:

  • Endocrinology
  • Cell Biology
  • Diabetology

Background:

  • The renin-angiotensin system (RAS) is activated in diabetes, increasing oxidative stress in pancreatic beta cells.
  • The angiotensin-converting enzyme 2 (ACE2)/angiotensin (1-7) [Ang (1-7)]/Mas axis negatively regulates the classical RAS.

Purpose of the Study:

  • To investigate the antioxidant effects of Ang (1-7) on pancreatic beta cells under oxidative stress conditions.

Main Methods:

  • INS-1 cells were cultured and exposed to hydrogen peroxide (H2O2) to induce oxidative stress.
  • Effects of Ang (1-7) on glucose-stimulated insulin secretion (GSIS), reactive oxygen species (ROS) generation, mitochondrial membrane potential (MMP), and glucose-stimulated calcium (GSCa) responses were assessed.
  • The role of the Ang (1-7) receptor was evaluated using its antagonist, A779.

Main Results:

  • H2O2 impaired GSIS, increased ROS production, and decreased GSCa and MMP in beta cells.
  • Pre-treatment with Ang (1-7) alleviated H2O2-induced damage.
  • The protective effects of Ang (1-7) were blocked by the antagonist A779.

Conclusions:

  • Ang (1-7) exhibits significant antioxidant effects, protecting pancreatic beta cells from oxidative injury.
  • This protection is mediated through the ACE2/Ang (1-7)/Mas axis and can be inhibited by A779.

More Related Videos

Isolated Pancreatic Islet Treatment and Apoptosis Measurement09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

1000
High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds12:32

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds

Published on: January 23, 2018

13.1K

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
3.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K